INZY — Inozyme Pharma Income Statement
0.000.00%
Last trade - 00:00- $257.60m
- $219.11m
Annual income statement for Inozyme Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 57 | 56.6 | 68.7 | 75.6 | 104 |
| Operating Profit | -57 | -56.6 | -68.7 | -75.6 | -104 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -56.4 | -56.6 | -67.1 | -71.2 | -102 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -56.4 | -56.6 | -67.1 | -71.2 | -102 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -56.4 | -56.6 | -67.1 | -71.2 | -102 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -56.4 | -56.6 | -67.1 | -71.2 | -102 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.41 | -2.4 | -1.78 | -1.37 | -1.62 |